Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL by Casado, JL et al.
POSTER PRESENTATION Open Access
Switching from tipranavir (TPV) 500/ritonavir
(RTV) 200 mg to TPV 500/RTV 100 mg in
treatment-experienced patients (pts) with HIV
RNA <50 copies/mL
JL Casado
1, P Domingo
2, R Rubio
3, A Antela
4, MA Lopez-Ruz
5, A Castro
6, J Portilla
7, E Ribera
8, D Podzamczer
9,
JA Oteo
10, J Galindo
11, S Otero
12, F Lozano
13, V Estrada
14, J Moltó
15, S Moreno
1*
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Background
The administration of 200 mg of RTV to boost TPV
plasma levels is associated with poor tolerance and toxi-
city. Some studies have shown that 100 mg of RTV
could be enough to reach plasma levels of TPV that
inhibit most HIV strains. This clinical trial was designed
to show the efficacy and tolerability of switching to TPV
500/RTV 100 in patients with suppressed viremia receiv-
ing TPV 500/RTV 200.
Methods
Open, randomized, multicenter clinical trial. Pts who
were receiving TPV 500/RTV 200 with an HIV RNA<50
copies/mL for at least 6 months and with a genotypic
sensitivity score showing activity of TPV were rando-
mized to continue on the same dose or to switch to
TPV 500/RTV 100 mg. The efficacy endpoint was the
proportion of pts with HIV RNA<50 copies/mL at 48
weeks in an ITT analysis. Discontinuation due to intol-
erance, liver toxicity and lipid abnormalities were also
evaluated. TPV plasma trough levels were measure in all
the patients.
Results
35 pts were randomized: 16 pts continued on TPV 500/
RTV 200 mg while 19 pts were switched to the lower
TPV 500/RTV 100 mg dose. At baseline, 48% had
AIDS, and mean CD4 count was 515 cells/mm
3.C o i n -
fection with HCV was more frequent in pts who
continued on the 200 mg RTV group (44%) than in
those that switched to the 100 mg RTV group (11%)
(p=0.02). Pts had received a median of 10 drugs (includ-
ing 3.6 PI), and mean duration of TPV therapy was 32
months. Mean number of accompanying drugs was 3.4
in the two groups. Mutations in RT and PRO before
initiating therapy with TPV were found in 31% and 20%
pts, respectively. After 48 weeks, HIV RNA remained
below 50 copies/mL in 89.5% pts in the RTV100 group
and in 75% in the RTV200 group [ITT, difference 14.5%
(95%CI -10.5, 39.5%)]. Mean CD4 count change was
+24 in the RTV100 group, and -33 in the RTV200
group (p=0.5). A greater decrease in GPT, total choles-
terol, and triglycerides was observed in the RTV100
group. One pt on the lower dose developed grade 2
increase in total cholesterol, while 3 pts developed grade
2-4 toxicities in the higher dose group (grade 2 and 4
hypertriglyceridemia, grade 2 hypertransaminemia).
Median TPV trough levels at 48 weeks were 38854 ng/
mL and 25465 ng/mL in the RTV 200 and RTV 100
groups, respectively.
Conclusions
Switching from TPV 500/RTV 200 mg to TPV 500/RTV
100 mg in treatment-experienced patients with HIV
RNA <50 copies/mL maintains virological suppression,
while improving liver and lipid abnormalities.
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